Overview

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Status:
Completed
Trial end date:
2017-02-15
Target enrollment:
Participant gender:
Summary
The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Atorvastatin
Atorvastatin Calcium
Simvastatin